Biotechnology main Biocon has reported 86.29 per cent bounce in consolidated revenue to Rs 296.4 crore for the quarter ended March 31, 2021.
The corporate had reported revenue of Rs 159.1 crore within the corresponding interval a yr in the past.
Complete earnings of the corporate rose by 26.13 per cent to Rs 2,044.1 crore as towards Rs 1,620.6 crore for a similar interval yr in the past, the corporate stated in a regulatory submitting.
Kiran Mazumdar-Shaw, Government Chairperson of Biocon, stated: “In Q4FY21 our revenues grew 26 per cent year-on-year to Rs 2,044 crore pushed by our biosimilars, analysis providers and generics companies”.
Mazumdar-Shaw stated the Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb.
“Syngene by its vaccination centre is providing immunisation providers for Biocon Group staff as properly to others working in Digital Metropolis, Bengaluru. Regardless of the challenges posed by the second COVID-19 wave in India, we’ll endeavour to have protected and uninterrupted operations and allow entry to life-saving medicines for our sufferers and clients,” she added.
In a separate submitting, the corporate stated its board of administrators has authorized the stepping down of Anupam Jindal as Chief Monetary Officer (CFO) with fast impact.
The board additionally cleared the appointment of Indranil Sen as CFO with fast impact.
Shares of Biocon have been buying and selling 1.47 per cent larger at Rs 396.70 apiece on BSE.